Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1 study of E7386 combinations in solid tumors
2023-510275-64-00Phase 2Authorised
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of e7386, lenvatinib, paclitaxel and doxorubicin in hepatocellular carcinoma (HCC), colorectal cancer (CRC), endometrial cancer (EC) and 1 more (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Safety, dose-limiting toxicities, and recommended phase 2 dose and Objective response rate. Planned start May 2023; status: authorised.
02
Drugs
e7386lenvatinibpaclitaxeldoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)endometrial cancer (EC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-510275-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510275-64-00.